Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
81P - The influence of comorbidity on health utility score (HUS) and health-related quality of life (HRQoL) in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC) (ID 531)
12:30 - 13:00 | Author(s): G. O'Kane
A significant number of patients with SCLC suffer from comorbidities. In particular, heart failure and chronic obstructive pulmonary disease are often present. Comorbidity alone has been validated as an independent negative survival prognostic factor in SCLC. Despite this, comorbidities are rarely systematically assessed in relation to quality of life. Here, we examine the effect of comorbidity on HUS and quality of life in SCLC in relation to NSCLC.
Histologically confirmed SCLC or NSCLC, were recruited from the Princess Margaret Cancer Centre. Demographics, treatment toxicity, and Patient Reported Charlson Comorbidity Index (PRO-CCI) were collected. For statistical analysis, univariable linear regression was applied to evaluate each variable and its association with HUS. A multivariable model with a backwards selection algorithm of univariable factors associated with HUS was employed.
Comorbidiity differentially drives HUS in SCLC compared to NSCLC (interaction p < 0.0001) and is an independent negative predictor of HRQoL (Table). Specifically, heart failure and COPD were two main modulators in SCLC quality of life (p < 0.05). Other prognostic factors, notably treatment-related symptom severity and performance status at diagnosis, did not differentially modulate HUS (Table). SCLC patients had a significantly higher number of comorbidities and lower HUS relative to NSCLC; nonetheless, comorbidity had the greatest magnitude of inverse relationship with HUS.
Interaction Terms Interaction p-value SCLC NSCLC CCI <0.0001 −0.09 (−0.01, −0.06) −0.02 (−0.05, 0.01) Average severity of symptoms 0.70 −0.04 (−0.06, −0.02) −0.04 (−0.05, −0.02) Performance status at diagnosis 0.53 −0.06 (−0.11, −0.02) −0.08 (−0.12, −0.05)
Comorbidity differentially modulates HUS in SCLC compared to NSCLC and is an important criterion to evaluate prior to treatment. We suspect that extensive smoking histories in the SCLC population may be driving these differential effects on HUS (Table). Interactions between factors differentially modulating HUS in SCLC and NSCLC.
Clinical trial identification:
Legal entity responsible for the study:
Princess Margaret Hospital (University Health Network)
Has not received any funding
All authors have declared no conflicts of interest.